Charnwood Molecular has appointed Francesca Sadler Chief Commercial Officer (CCO). Sadler will lead all commercial activities across business development, sales, and marketing. Charnwood Molecula is a pre-clinical CRO specializing in enhancing the experience and success of complex drug discovery for clients globally.

“Charnwood Molecular continues to see strong growth in its drug discovery services as our clients look to partner with our highly skilled and experienced team,” said Lee Patterson, CEO.

“I’m delighted Francesca is joining the Charnwood Molecular Board and executive leadership team in this critical role as we embark on the next phase of our growth. She brings extensive industry experience and the highest standards of customer service which, combined with her stellar track record in the life sciences sector, will allow us to meet the increased demand for our services, enabling more of our clients to benefit from the enhanced experience and industry leading scientific value we add to their drug discovery programs.”

Ben Cons, chairman said, “This is a pivotal appointment with Francesca focusing on executing and accelerating Charnwood Molecular’s global business growth strategy. I look forward to working with her to achieve our aims.”

“This is a fantastic opportunity to be part of a company that has grown so much in the last three years and is now an established partner of choice for leading biotech companies requiring fully integrated drug discovery CRO services,” said Sadler. I believe that Charnwood Molecular offers valuable stand-alone services to companies looking for intellectual input and innovation as part of their research programs, with a compelling ‘under-one-roof’ solution.”

Francesca joins Charnwood Molecular from Eurofins Discovery where she most recently served as senior vice president commercial with responsibilities across Europe, North America. and Asia. This follows a distinguished career in senior roles at companies including Cyprotex, Aptuit and Charles River Discovery.

Sadler’s appointment comes a year after the company’s move to world-class facilities at Charnwood Campus and the addition of DMPK to its portfolio of drug discovery services.